TAIPEI (TVBS News) — Taiwan's decision to cover a gene therapy treatment costing NT$100 million (around US$3.2 million) per dose for a rare fatal disease has sparked debate over healthcare funding. The National Health Insurance Administration (NHIA), Taiwan's healthcare oversight agency, announced coverage for aromatic L-amino acid decarboxylase (AADC) deficiency treatment in August. The decision raises questions about whether society should collectively bear the costs of treating rare diseases.
The NHIA announced in August it would reimburse patients for gene therapy containing eladocagene exuparvovec to treat AADC deficiency, a rare genetic disease. The treatment reaches NT$100 million (around US$3.2 million) per dose for each patient receiving therapy. Public debate centers on whether taxpayers should bear the cost of expensive treatments for rare genetic diseases that affect relatively few patients nationwide.
AADC deficiency causes severe developmental delays and oculogyric crises, where eyes shoot upwards involuntarily, plus multiple nervous system complications. The symptoms stem from the body's inability to produce dopamine, an important neurotransmitter essential for motor function and development. Many patients die before reaching adulthood without treatment for this rare genetic disorder affecting neural development and basic bodily functions.
The gene therapy containing eladocagene exuparvovec spurs dopamine production and promotes motor function development for patients with AADC deficiency. The European Union approved the drug for clinical use in 2022 following extensive trials. The U.S. approved it only last year, making it a relatively new treatment option for this rare genetic disorder affecting children.
The NHIA decided to cover eladocagene exuparvovec for children with AADC deficiency based on clinical results. The agency covers one treatment per child in their lifetime. The NHIA expects to treat 13 children next year and roughly five children annually afterwards, costing NT$1.3 billion (around US$41.8 million) initially and NT$500 million (around US$16.1 million) yearly.
The drug's high cost has sparked debate over whether the public should bear the expense of rare disease treatments for a few patients. Some critics argue that supporting the inclusion of rare diseases contradicts the public backlash against government proposals to raise insurance premiums for funding. Taiwan's aging population and shrinking workforce will strain the NHIA further over time, as the insurance fund relies largely on salary deductions.
Critics argue other rare diseases with available treatments remain uncovered by the NHIA despite patient needs. One Facebook comment questioned the fairness of covering AADC deficiency treatments but not diseases like diffuse panbronchiolitis affecting more patients. Another commenter raised doubts about the majority of society paying for treatments affecting only a small minority of patients nationwide.
Some advocates have argued for coverage of this expensive treatment despite the significant financial costs to taxpayers. One doctor argued that including gene therapy within Taiwan's national healthcare system would generate high-quality medical data for research. He noted this is crucial given the lack of East Asian representation in international gene banks and could boost Taiwan's drug development sector.
Other commenters noted the drug has been shown to drastically extend patients' lifespans and functional development. Such treatments could be a patient's only hope for better quality of life and normal development. These expensive treatments may only be accessible to families through healthcare coverage, and better outcomes substantially impact the quality of life for patients' families.
NHIA Director Lian-Yu Chen (陳亮妤) reiterated that coverage was determined through a fair and transparent review process amid the public controversy over the drug’s cost. The agency plans to negotiate installment payment arrangements with the drug manufacturer after several years, based on price and volume agreements. The gene therapy containing eladocagene exuparvovec has been available for patients since early December this year.
Patients with AADC deficiency will have a lifeline for longer and better lives for at least the next few years. The debate over financial costs has highlighted long-standing funding issues facing Taiwan's national healthcare system amid demographic challenges. The treatment offers patients a chance that many consider priceless despite ongoing funding challenges for the NHIA. ◼ (At time of reporting, US$1 equals approximately NT$31.1)